Actively Recruiting
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Led by Rajiv Gandhi Cancer Institute & Research Center, India · Updated on 2025-01-17
124
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
Sponsors
R
Rajiv Gandhi Cancer Institute & Research Center, India
Lead Sponsor
V
Varian, a Siemens Healthineers Company
Collaborating Sponsor
AI-Summary
What this Trial Is About
DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.
CONDITIONS
Official Title
Dose Escalation Using Hypoxia-adjusted Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Willingness to sign informed consent (written or video documentation)
- ECOG performance status of 0 to 2
- Histologically confirmed squamous cell carcinoma
- Tumor located in oral cavity, oropharynx, hypopharynx, or larynx
- Any tumor grade and gender
- Adequate bone marrow function within last 14 days: hemoglobin >10 g/dl (corrected), total leukocyte count >4,000 per cumm, platelet count >150,000 per cumm
- Normal liver and kidney function
- Nutritional and dental assessment before enrollment
You will not qualify if you...
- HPV (p16) positive tumors
- Prior surgery or radiation therapy for any head and neck cancer
- T1 or T2 glottis tumors
- Metastatic disease or disease unfit for definitive locoregional treatment
- Medical conditions preventing radiation or cisplatin chemotherapy
- Pregnancy or lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rajiv Gandhi Cancer Institute and Research Centre
Delhi, India, 110085
Actively Recruiting
Research Team
S
Sarthak Tandon, DNB
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here